COST-EFFECTIVENESS OF NILOTINIB VERSUS IMATINIB AS FIRST-LINE TREATMENT FOR NEWLY DIAGNOSED PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE (CML-CP) IN RUSSIAN FEDERATION

被引：0
|
作者：
Yagudina, R. [1 ]
Kulikov, A. [1 ]
Komarov, I [1 ]
机构：
[1] IM Sechenov First Moscow State Med Univ, Moscow, Russia
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.2132
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A426 / A426
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of imatinib (GLEEVEC) as first-line treatment in chronic myeloid leukemia (CML)
    El Quagari, K
    Talbot, W
    Baladi, JF
    VALUE IN HEALTH, 2004, 7 (06) : 669 - 669
  • [22] Use Of Nilotinib As a First Line Treatment In Adult Patients With Philadelphia Chromosome-Positive and Chronic Phase Myeloid Leukemia
    Saydam, Guray
    Haznedaroglu, Ibrahim C.
    Kaynar, Leylagul
    Yavuz, Akif S.
    Ali, Ridvan
    Guvenc, Birol
    Akay, Olga M.
    Baslar, Zafer
    Ozbek, Ugur
    Sonmez, Mehmet
    Aydin, Demet
    Pehlivan, Mustafa
    Undar, Bulent
    Dagdas, Simten
    Ayyildiz, Orhan M.
    Akkaynak, Diyar Z.
    Dag, Ilkiz M.
    Ilhan, Osman
    BLOOD, 2013, 122 (21)
  • [23] A phase II study of dasatinib therapy in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CML-CP) or Philadelphia chromosome-positive (Ph plus ) leukemias resistant or intolerant to imatinib.
    Zwaan, Michel
    Stork, Linda C.
    Bertrand, Yves
    Gore, Lia
    Hijiya, Nobuko
    De Souza, Carmino
    Lee, Maria Lucia de Martino
    Bradley-Garelik, M. Brigid
    Kearns, Pamela
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] COST-EFFECTIVENESS ANALYSIS OF NILOTINIB VERSES IMATINIB FOR THE TREATMENT OF CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKAEMIA
    Mildred, M.
    Ward, S.
    Squires, H.
    Gray, E.
    HAEMATOLOGICA, 2012, 97 : 314 - 314
  • [25] Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update
    Larson, Richard A.
    Hochhaus, Andreas
    Saglio, Giuseppe
    Kim, Dong-Wook
    Jootar, Saengsuree
    Le Coutre, Philipp D.
    Reiffers, Josy
    Pasquini, Ricardo
    Goldberg, Stuart L.
    Clark, Richard E.
    Kemp, Charisse N.
    Fan, Xiaolin
    Menssen, Hans D.
    Hughes, Timothy P.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Imatinib mesylate (STI571) therapy of Philadelphia chromosome-positive chronic myeloid leukemia in early chronic phase (Ph plus CML early CP).
    Kantarjian, HM
    Cortes, J
    O'Brien, S
    Giles, F
    Thomas, D
    Garcia-Manero, G
    Faderl, S
    Rios, MB
    Shan, J
    Hayes, K
    Keating, MJ
    Freireich, EJ
    Talpaz, M
    BLOOD, 2001, 98 (11) : 137A - 137A
  • [27] Efficacy of nilotinib (AMN107) in patients (Pts)with newly diagnosed, previously untreated philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP)
    Cortes, Jorge
    O'Brien, Susan
    Jabbour, Elias
    Ferrajoli, Alexandra
    Borthakur, Gautam
    Burger, Jan
    Wierda, William
    Garcia-Manero, Guillermo
    Thomas, Michelle
    Letvak, Laurie
    Kantarjian, Hagop
    BLOOD, 2007, 110 (11) : 17A - 17A
  • [28] MODELING THE SURVIVAL LOSS IN PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE (PH plus ) CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) SWITCHED FROM IMATINIB MESYLATE TO A GENERIC COPY
    Botteman, M.
    Magestro, M.
    Alwan, A. F.
    VALUE IN HEALTH, 2012, 15 (07) : A422 - A422
  • [29] Frequency and Impact of Molecular Response's with Nilotinib (Tasigna) in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP)
    Daver, Naval
    Kantarjian, Hagop M.
    O'Brien, Susan
    Jabbour, Elias
    Pierce, Sherry
    Lim, Miranda
    Borthakur, Gautam
    Pemmaraju, Naveen
    Konopleva, Marina
    DiNardo, Courtney D.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    BLOOD, 2014, 124 (21)
  • [30] CONTINUED SUPERIORITY OF NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTND BEYOND 1 YEAR
    Hochhaus, A.
    Lobo, C.
    Pasquini, R.
    Clark, R.
    Kim, D. W.
    Issaragrisil, S.
    le Coutre, P.
    Reiffers, J.
    Kantarjian, H.
    Saglio, G.
    Edrich, P.
    Hoenekopp, A.
    Gallagher, N.
    Larson, R.
    Hughes, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 459 - 459
12345